Adalimumab: study card

Generic name

Adalimumab

Class

TNF blocker (monoclonal antibody)

Mechanism

Binds TNF-alpha and blocks its interaction with p55 and p75 cell surface TNF receptors.

Used for

Moderately to severely active rheumatoid arthritis in adults; Moderately to severely active polyarticular juvenile idiopathic arthritis in patients aged 2 years and older

Common side effects

Infections (URI, sinusitis); Injection site reactions; Headache; Rash

Boxed warning

Serious infections and malignancy; risk of hospitalization or death.

Warnings

Serious and invasive fungal infections; Malignancies; Anaphylaxis / hypersensitivity

Interactions

Abatacept; Anakinra; Live vaccines

Label date: 20260807 · For learning, not clinical decisions. US label and brand information; always consult the current source.

Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.